Survivin反义寡核苷酸抑制肝癌移植瘤生长的作用

目的:检测Survivin反义寡核苷酸(ASODN)在人肝癌耐药细胞株裸鼠皮下移植瘤中的表达情况．方法:将30只裸鼠建立人肝癌耐药细胞系 SMMC-7721／ADM皮下移植瘤模型,随机分成6组:空白对照组(A)、脂质体转染对照组 (B)、正义链对照组(C)、200(D)、400(E)和 600 μg/L(F)反义链组(ASODN组),用不同的转染液注射后2,4,8,12,16,20 d,用逆转录聚合酶链反应技术(RT-PCR)和Western blot蛋白免疫印迹法检测治疗后各组肿瘤组织中Survivin mRNA和蛋白表达的变化．结果:注射后20 d,ASODN组肿瘤细胞生长明显抑制,空白对照组、脂质体转染对照组和正义链对照组裸鼠的mRNA和蛋白表达无明显差异,而ASODN组mRNA和蛋白表达随着时间和浓度的增加,Survivin表达减弱,E,F组与其余个组(A,B,C,D)相比有显著差异(mRNA: 0．33±0．04,0．28±0．03 vs 0．82±0．02,0．78± 0．05,0．72±0．04,0．57±0．03,P<0．05;蛋白: 34．9±3．89,21．2±3．65 vs 72．14±6．53,69．31 ±5.34,68．29±4．98,53．8±5．23,P<0．05)．结论:Survivin反义寡核苷酸能够下调 Survivin mRNA和蛋白的表达,抑制裸鼠皮下移植瘤的生长．     

Fibronectin and circulating immune complexes in Behçet's disease

Being a high-molecular-weight adhesive glycoprotein, fibronectin (Fn) is suggested to be a component of immune complexes and may participate in the clearance of immune complexes. In Behçet's disease (BD), a multisystem disorder of unknown etiology, immune complexes have been shown to be deposited in affected tissue during disease activity, suggesting an immune mechanism. This study investigates the relationship between Fn and circulating immune complexes (CIC) and evaluates the changes in the levels of Fn and CIC along with disease activity. In 63 patients (31 active, 32 inactive) with BD, plasma Fn and serum CIC, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and the third and fourth components of the complement system (C3, C4) were studied. The mean ESR, CRP, C3 and C4 levels of active BD patients were found to be significantly higher than those of the inactive BD patient group. Although the mean Fn and CIC levels of BD patients were not significantly different from those of the healthy control group, Fn and CIC values of active BD patients were significantly lower than in the inactive group. Moreover, no significant correlation was observed among Fn levels and ESR, CRP, C3, C4 and CIC levels in BD patients. The result of this study suggest that the variation in Fn concentration is independent of the acute-phase response. The lack of relationship between the CIC and Fn concentrations indicates that IC deposition in the vessel wall is independent of the CIC levels. In order to determine the exact roles of Fn and IC, further studies in tissue specimens are required.     

亲情关系与心脑血管疾病

目的:探讨亲情因素对心脑血管疾病发病的影响。方法:对212例老干部进行无记名问卷调查。内容包括:夫妻间性格、经济支配权、夫妻性生活、夫妻间感情与子女交谈及子女的孝敬6项因素,其程度分好、一般、不好三个层面。结果:夫妻间经济支配权、性格与子女交谈多少对心脑血管病的发生影响较小(P>0．05);夫妻间感情、性生活和谐度和子女的孝敬程度对发病影响大(P<0．05)。结论:应重视夫妻间的感情和性生活的和谐程度,子女的孝敬程度,以减少心脑血管疾病发病率。     

通脉颗粒对兔动脉粥样硬化模型血脂水平及主动脉和冠状动脉病变的影响

目的观察通脉颗粒对动脉粥样硬化兔模型血脂水平及主动脉和冠状动脉病变的影响。方法将40只日本大耳白兔随机分为空白对照组、模型对照组、通脉颗粒小刺量组、通脉颗粒大刺量组，每组10只，空白组普通饲料喂养，其余各组予高脂饮食（含5％猪油、0．5％胆固醇）喂养12周复制成动脉粥样硬化模型，其中后两组同时予大小剂量通脉颗粒灌胃，观察各组动物实验前后血脂水平变化及主动脉和冠状动脉病理形态改变（包括主动脉粥样斑块厚度、斑块覆盖面积和冠状动脉狭窄状况）。结果各模型组动物在实验结束时血浆甘油三酯、总胆固醇、低密度脂蛋白均明显上升，但通脉颗粒干预组上升幅度低于模型组，其中大剂量组上升幅度最小。与其他各组比较有显著性差异（P〈0．05）；空白对照组主动脉、冠状动脉正常，其余各组均有不同程度粥样斑块形成和冠状动脉狭窄，主动脉斑块厚度、斑块覆盖面积占整条主动脉面积的百分比蜞基狭窄冠状动脉百分比，大小剂量组均比模型组小，而大剂量组最小（P〈0．05）。结论通脉颗粒可显著降低动脉粥样硬化兔模型的血脂水平、延缓动脉粥样斑块的发生发展，这可能是该药治疗冠心病心绞痛的重要机理之一。     

三磷酸腺苷结合盒转运子A1基因多态性R219K与脂代谢及冠心病易感性的相关性

目的　探讨三磷酸腺苷结合盒转运子A1基因R2 19K单核苷酸多态性位点与脂代谢和冠状动脉粥样硬化性心脏病易感性的关系。方法　采用聚合酶链反应—限制片长多态性方法检测 133名正常人和 4 9名家族性高胆固醇血症患者三磷酸腺苷结合盒转运子A1基因相应片段的多态性。结果　家族性高胆固醇血症患者组三磷酸腺苷结合盒转运子A12 19K等位基因频率显著低于正常人群 (P =0 .0 0 0 1)。家族性高胆固醇血症患者组中 ,K等位基因携带者组 (RK基因型 +KK基因型组 )与RR基因型组比较 ,甘油三酯水平明显降低 (1.14± 0 .5 5mmol/L比 1.76± 0 .5 8mmol/L ,P =0 .0 0 1) ,高密度脂蛋白胆固醇水平有增高趋势 (1.39± 0 .5 4mmol/L比 1.2 1± 0 .32mmol/L ,P =0 .0 6 1)。结论　三磷酸腺苷结合盒转运子A1基因R2 19K多态性中 ,2 19K等位基因与家族性高胆固醇血症患者甘油三酯水平降低和高密度脂蛋白胆固醇水平增高相关联 ,可能对家族性高胆固醇血症患者不早发冠心病起保护作用     

In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility

The aim of this study was to evaluate whether the serum concentration of interleukin-6 (IL-6) reflects disease activity in ankylosing spondylitis (AS). A group of 271 AS patients were enrolled in the study, 261 of whom completed the entire protocol (201 males, 60 females, median age of 53 years). Serum IL-6 was measured three times (I, baseline; II, after 10 – 12 days; III, after 17 – 24 days) during a 3- or 4-week treatment at the health resort. At the same times, the variables for mobility were measured, and the patients were asked to assess their complaints (score) in a self-styled questionnaire. The serum concentration of IL-6 correlated with the measurements of occiput-to-wall distance, cervical rotation, finger-floor distance and Schober sign, and with morning pain at all three evaluations. Comparisons between changes in IL-6 and changes in the variables (measures of mobility, scores of the questionnaires) did not reveal significant correlations. Present data would suggest that in AS the serum concentration of IL-6 indicates the degree of mobility restriction resulting from previous disease progression, but is not a reliable marker of current disease activity. Received: 10 February 1998 / Accepted: 9 July 1998     

糖尿病与血管钙化

血管钙化是糖尿病患者的一个常见并发症,包括血管内膜钙化和中膜钙化,呈进展性,是糖尿病患者心血管疾病及全因死亡的预测因子。糖尿病血管钙化是多种促进和抑制钙化的因素参与的细胞介导的主动调节过程,高血糖、胰岛素抵抗、肾脏疾病、炎症、骨相关蛋白表达异常等多种因素与其相关。对于糖尿病血管钙化,目前尚无有效的治疗手段,及时评价和控制血管钙化的危险因素,进行合理的预防性治疗非常重要。     

大骨节病区FA对软骨细胞ALPase活性的影响

为探明大骨节病病区黄腐酸（Ｆｕｌｖｉｃａｃｉｄ，ＦＡ）对软骨内成骨过程中矿化的影响，采用４－甲基伞形酮磷酸酯（４－ＭｅｔｈｙｌｕｍｂｅｌｌｉｆｅｒｙｌＰｈｏｓｐｈａｔｅ，４－ＭＵＰ）为碱性磷酸酶（ＡｌｋａｌｉｎｅＰｈｏｓｐｈａｔａｓｅ，ＡＬａｓｅ）作底物，并结合Ｇｏｍｏｒｉ染色法，研究了ＦＡ对体外培养的肥大软骨细胞及基质在矿化过程中ＡＬＰａｓｅ活性影响。发现与视黄酸（Ｒｅｔｉｎｏｉｃａｃｉｄ，ＲＡ     

Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable,male patients show more radiographic progression during treatment with TNF-α inhibitors

Background

The clinical presentation of ankylosing spondylitis (AS) differs between genders. Our aim was to investigate differences in disease activity, disease outcome and treatment response between male and female AS patients before and after starting tumor necrosis factor (TNF)-α inhibitors in daily clinical practice.

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children

BACKGROUND AND AIMS: The REACH study evaluated the safety and efficacy of infliximab in children with moderately to severely active Crohn's disease. METHODS: Patients (n = 112) with a Pediatric Crohn's Disease Activity Index (PCDAI) score >30 received infliximab 5 mg/kg at weeks 0, 2, and 6. Patients responding to treatment at week 10 were randomized to infliximab 5 mg/kg every 8 or 12 weeks through week 46. A concurrent immunomodulator was required. Clinical response (decrease from baseline in the PCDAI score > or =15 points; total score < or =30) and clinical remission (PCDAI score < or =10 points) were evaluated at weeks 10, 30, and 54. RESULTS: At week 10, 99 of 112 (88.4%) patients responded to infliximab (95% confidence interval: [82.5%, 94.3%]) and 66 of 112 (58.9%) patients achieved clinical remission (95% confidence interval: [49.8%, 68.0%]). At week 54, 33 of 52 (63.5%) and 29 of 52 (55.8%) patients receiving infliximab every 8 weeks did not require dose adjustment and were in clinical response and clinical remission, respectively, compared with 17 of 51 (33.3%) and 12 of 51 (23.5%) patients receiving treatment every 12 weeks (P = .002 and P < .001, respectively). CONCLUSIONS: Pediatric patients responding to an induction regimen of infliximab were more likely to be in clinical response and remission at week 54 without dose adjustment when their maintenance therapy was given every 8 weeks rather than every 12 weeks. Allowing for dose intensification in the case of relapse, remission rates, but not response rates, at week 54 were superior with every 8-week dosing compared with every 12-week dosing.